Nutra Pharma (NPHC) 10-K 15 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Apr. 15, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-32141
Entity Registrant Name	NUTRA PHARMA CORP.
Entity Central Index Key	0001119643
Entity Tax Identification Number	91-2021600
Entity Incorporation, State or Country Code	CA
Entity Address, Address Line One	1537 NW 65th Ave
Entity Address, City or Town	Plantation
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33313
City Area Code	(954)
Local Phone Number	509-0911
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 5,755,920
Entity Common Stock, Shares Outstanding		7,363,852,214
Auditor Name	Rotenberg Meril Solomon Bertiger & Guttilla, PC
Auditor Location	Saddle Brook, NJ
Auditor Firm ID	361

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 90,910
Accounts receivable	45,998	37,080
Inventory, current portion	31,289	5,271
Other receivable	6,000	3,000
Convertible notes receivable	273,480
Prepaid expenses and other current assets	86,150	10,000
Total current assets	533,827	55,351
Inventory, less current portion	98,880	78,880
Property and equipment, net	44,701	14,742
Operating lease right-of-use assets	93,811	144,010
Security deposit	8,803	8,803
Total assets	780,022	301,786
Current liabilities:
Accounts payable	672,372	599,428
Accrued expenses	851,470	780,432
Accrued payroll due to officers	1,053,693	1,429,693
Accrued interest to related parties	147,768	179,522
Due to officer	199,726	200,837
Derivative liabilities	10,537,344	3,567,176
Other debt, net of discount, current portion	7,598,325	4,631,921
SBA notes payable, current portion	2,121	10,725
Operating lease obligations, current portion	77,673	82,873
Total current liabilities	21,140,492	11,482,607
Convertible notes, less current portion	369,401	48,477
SBA notes payable, less current portion	147,779	204,070
Operating lease obligations, less current portion		60,447
Total liabilities	21,657,672	11,795,601
Commitments and Contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 12,000,000,000 and 8,000,000,000 shares authorized: 7,330,985,964 and 6,955,197,214 shares issued and outstanding at December 31, 2021 and 2020	7,330,986	6,955,197
Additional paid-in capital	53,508,353	50,181,456
Accumulated deficit	(81,728,989)	(68,633,468)
Total stockholders’ deficit	(20,877,650)	(11,493,815)
Total liabilities and stockholders’ deficit	780,022	301,786
Series A Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value		3,000
Series B Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	$ 12,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	12,000,000,000	8,000,000,000
Common stock, shares issued	7,330,985,964	6,955,197,214
Common Stock, Shares, Outstanding	7,330,985,964	6,955,197,214
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	0	20,000,000
Preferred stock, shares issued	0	3,000,000
Preferred stock, shares outstanding	0	3,000,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	0
Preferred stock, shares issued	12,000,000	0
Preferred stock, shares outstanding	12,000,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales	$ 97,735	$ 51,897
Cost of sales	(41,268)	(15,678)
Change in reserve for supplier advances for purchases	(48,000)	(21,303)
Gross profit	8,467	14,916
Operating expenses:
Selling, general and administrative - including stock based compensation of $153,500 and $8,500 for the years ended December 31, 2021 and 2020, respectively	1,928,582	1,101,363
Bad debt expense (recovery) -related party	68,330	(161,500)
Total operating expenses	1,996,912	939,863
Loss from operations	(1,988,445)	(924,947)
Other income (expenses)
Other income	78,254	5,000
Interest expense	(477,433)	(316,207)
Interest expense to related parties	(18,246)	(19,967)
Change in fair value of convertible notes and derivatives	(10,096,315)	(1,012,556)
Stock based loan modification cost	(107,500)	(87,800)
(Loss) gain on settlement of debt and accrued expense, net	(485,836)	1,587,293
Total other income (expenses)	(11,107,076)	155,763
Loss before income taxes	(13,095,521)	(769,184)
Provision for income taxes
Net loss	$ (13,095,521)	$ (769,184)
Net loss per share - basic and diluted	$ 0	$ 0
Weighted average number of shares outstanding during the year - basic and diluted	7,232,591,111	6,607,482,758

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Stock based compensation	$ 153,500	$ 8,500

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2019	$ 3,000		$ 5,876,746	$ 50,283,503	$ (67,864,284)	$ (11,701,035)
Balance, shares at Dec. 31, 2019	3,000,000		5,876,746,111
Common stock issued for debt modification and penalty			$ 138,500	(50,700)		87,800
Common stock issued for debt modification and penalty, shares			138,500,000
Common stock issued for conversion of debt			$ 814,951	(13,847)		801,104
Common stock issued for conversion of debt, shares			814,951,103
Common stock issued for settlement of debt			$ 125,000	(37,500)		87,500
Common stock issued for settlement of debt, shares			125,000,000
Net loss					(769,184)	(769,184)
Balance at Dec. 31, 2020	$ 3,000		$ 6,955,197	50,181,456	(68,633,468)	(11,493,815)
Balance, shares at Dec. 31, 2020	3,000,000		6,955,197,214
Common stock issued for debt modification and penalty			$ 25,000	82,500		107,500
Common stock issued for debt modification and penalty, shares			25,000,000
Common stock issued for conversion of debt			$ 240,350	2,104,049		2,344,399
Common stock issued for conversion of debt, shares			240,350,000
Common stock issued for settlement of debt			$ 62,939	472,848		535,787
Common stock issued for settlement of debt, shares			62,938,750
Net loss					(13,095,521)	(13,095,521)
Exchange of Series A Preferred Stock for Series B Preferred stock	$ (3,000)	$ 3,000
Exchange of Series A Preferred Stock for Series B Preferred stock, shares	(3,000,000)	3,000,000
Series B Preferred Stock issued in exchange for accrued salary		$ 9,000		531,000		540,000
Series B preferred stock issued in exchange for accrued salary to a related party, shares		9,000,000
Common stock issued in exchange for services to consultants			$ 35,000	139,000		174,000
Common stock issued in exchange for services to consultants, shares			35,000,000
Common stock issued in exchange for accrued interest to a related party			$ 12,500	(2,500)		10,000
Common stock issued in exchange for accrued interest to a related party, shares			12,500,000
Balance at Dec. 31, 2021		$ 12,000	$ 7,330,986	$ 53,508,353	$ (81,728,989)	$ (20,877,650)
Balance, shares at Dec. 31, 2021		12,000,000	7,330,985,964

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (13,095,521)	$ (769,184)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in reserve for supplier advances for purchases	48,000	21,303
Bad debt expense (recovery) - related party	68,330	(161,500)
Accrued interest expense for amount due to officer	7,520	7,675
Loss on settlement of debt and accrued expense	485,836	(1,587,293)
Depreciation	9,084	3,831
Stock-based compensation	153,500	8,500
Stock-based loan modification cost	107,500	87,800
Amortization of convertible notes receivable discount	(12,980)
Forgiveness of PPP loan	(65,274)
Change in fair value of convertible notes and derivatives	10,096,315	1,012,556
Amortization of loan discount	326,391	130,485
Amortization of operating lease right-of-use assets	54,301	63,520
Changes in operating assets and liabilities:
Increase in accounts receivable	(8,920)	(4,601)
Increase in other receivable	(9,000)	(3,000)
Increase in inventory	(46,018)	(23,791)
Increase in prepaid expenses and other current assets	(103,650)	(15,906)
Increase in accounts payable	72,944	10,297
Increase in accrued expenses	94,676	214,235
Increase in accrued payroll due to officers	164,000	180,300
Increase (decrease) in accrued interest to related parties	(21,754)	19,967
Decrease in operating lease obligations	(69,749)	(73,280)
Net cash used in operating activities	(1,744,469)	(878,086)
Cash flows from investing activities:
Convertible notes receivable advances	(254,500)
Acquisition of equipment	(39,043)	(5,905)
Net cash used in investing activities:	(293,543)	(5,905)
Cash flows from financing activities:
Loans from officer	105,780	254,000
Repayment of officer loans	(182,741)	(22,150)
Repayments of notes payable-related party		(14,400)
Proceeds from convertible notes	2,288,560	527,983
Repayment of convertible notes	(67,302)	(5,782)
Advances from an unrelated third party		50,000
Repayments of other notes payable	(15,375)	(120,455)
Proceeds from SBA notes payable		214,795
Net cash provided by financing activities	2,128,922	883,991
Net increase in cash	90,910
Cash - beginning of period
Cash - end of period	90,910
Supplemental Cash Flow Information:
Cash paid for interest	42,677	1,049
Cash paid for income taxes
Non Cash Financing and Investing:
Common stock issued in settlement of notes and accrued expenses	535,787	87,500
Common stock issued for conversion of debt	2,344,399	801,104
Common stock issued to satisfy accrued interest-related party	10,000
Preferred stock issued satisfy accrued salary	540,000
Warrants issued with Debt--Debt discount	150,000	105,000
Purchase of equipment included in accounts payable		5,905
Increase of right-of-use asset due to lease renewal	4,102
Increase of operating lease liabilities due to lease renewal	4,102
Reclassification of accrued interest to debt		30,850
Reclassification of rental receivable to convertible notes receivable	$ 6,000

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. In October of 2021 we began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor. Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 81,728,989 20,606,665 20,877,650 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 48,000 21,303 294,162 246,162 Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2021, there was one customer that accounted for 21 37 100 Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7 Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2021 and 2020, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373 Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and 2020 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at December 31, 2021 and December 31, 2020: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Fair Value Measurements at December 31, 2021 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 189,543 $ 1,411 Purchases, issuances, and settlements 590,885 143,369 Total loss (gain) included in earnings (1) (69,843 ) 44,763 Total loss (gain) included in earnings (69,843 ) 44,763 Ending balance $ 710,885 $ 189,543 (1) The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.19 0.39 273 276 zero We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at December 31, 2021 and 2020, respectively. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2021 and 2020: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 2020 $ 766,101 8 10 20 24 N/A $ 0.00050 0.00064 50 60 3 25 Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 1,832,439 $ 5,814,047 Purchases and issuances 132,000 25,981 Day one loss on value of hybrid instrument (1) 2,042,612 318,174 Day one loss on value of hybrid instrument 2,042,612 318,174 Loss (gain) from change in fair value (1) 1,233,538 (1,931,927 Loss (gain) from change in fair value 1,233,538 (1,931,927 Gain on settlement - (1,609,294 Debt discount - 22,344 Repayments in cash (40,480 ) (5,782 ) Conversion to common stock (2,344,399 ) (801,104 ) Ending balance $ 2,855,709 $ 1,832,439 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES	3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2021 and 2020, inventories were as follows: SCHEDULE OF INVENTORIES December 31, 2021 December 31, 2020 Raw Materials $ 126,349 $ 78,880 Finished Goods 3,820 5,271 Total Inventories 130,169 84,151 Less: Long-term inventory (98,880 ) (78,880 ) Current portion $ 31,289 $ 5,271

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at December 31, 2021 and 2020: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 104,564 65,521 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 266,886 227,843 Less: Accumulated depreciation (222,185 ) (213,101 ) Property and equipment, net $ 44,701 $ 14,742 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At December 31, 2021, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the years ended December 31, 2021 and 2020 was $ 9,084 and $ 3,831 , respectively.

DUE TO_FROM OFFICER

DUE TO/FROM OFFICER	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
DUE TO/FROM OFFICER	5. DUE TO/FROM OFFICER At December 31, 2020, the balance due to our President and CEO, Rik Deitsch, was $ 200,837 4 22,150 254,000 7,675 161,500 402,970 At December 31, 2021, the balance due to Rik Deitsch, and the Companies owned by him is $ 199,726 , which is an unsecured demand loan that bears interest at 4 %. During the year ended December 31, 2021, we repaid $ 182,741 to and collected $ 105,780 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $ 7,520 and is included in the due to officer account. For the year ended December 31, 2021, we recorded a bad debt expense of $ 68,330 for the receivables from these Companies

DEBTS

DEBTS	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
DEBTS	6. DEBTS Debts consist of the following at December 31, 2021 and 2020: SCHEDULE OF DEBT December 31, 2021 December 31, 2020 Notes payable – Unrelated third parties (Net of discount of $ 0 1,500 $ 1,135,257 $ 1,346,057 Convertible notes payable – Unrelated third parties (Net of discount of $ 283,429 101,448 3,751,760 1,276,902 Convertible notes payable, at fair value (4) 2,855,709 1,832,439 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 214,795 Ending balances 8,117,626 4,895,193 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (369,401 ) (48,477 ) Less: Long-term portion- SBA notes payable (147,779 ) (204,070 ) Current portion $ 7,600,446 $ 4,642,646 (1) During 2010 we borrowed $ 200,000 nine months interest calculated at 10% for the first month plus 12% December 31, 2016 40,000 12,500,000 10,000 147,768 179,522 18,246 19,967 (2) At December 31, 2021 and 2020, the balance of $ 1,135,257 1,346,057 0 1,500 ● In August 2016, we issued two Promissory Notes for a total of $ 200,000 100,000 12% 101,818 21,023 104,000 88,500 15,500 88,500 91,156 51,856 40,917 The remaining principal balance of $91,156 and accrued interest of $51,856 is being disputed in court and negotiation for settlement ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $ 350,000 50,000 175,000 25,000 25,000 142,858 5,714,326 450,000 350,000 100,000 281,772 281,772 ● At December 31, 2012, we owed University Centre West Ltd. approximately $ 55,410 ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $ 10,000 10% 5,783 4,769 ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 75,000 2% 5,000,000 25,000 50,000 74,334 62,167 ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 50,000 67,534 55,367 ● A promissory note originally issued to an unrelated third party in August 2016 was restated in September 2019 in the amount of $ 333,543 bearing monthly interest at a rate of 2.0% 20,000,000 shares of our common stock. During September 2020, we issued a total of 10,000,000 restricted shares due to the default on repayments. The shares were valued at fair value of $ 6,000 . The common stock was valued at $ 5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount was fully amortized at December 31, 2020. The Note is in default and negotiation of settlement. At December 31, 2021 and 2020, the principal balance is $ 333,543 , and the accrued interest is $ 187,673 and $ 167,216 , respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $ 75,000 10% 15,000 60,000 15,900 15,000 1,371 ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $ 50,000 2% 63,834 51,667 ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $ 12,500 10% 5,750 4,483 ● During July 2017, we received a loan for a total of $ 200,000 15% 130,401 40,000 5,000 2,000 34,976 42,698 44,478 14,376 33,874 48,250 130,401 33,874 ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $ 50,000 10,000 50,000 ● During September 2018 and 2019, a promissory note originally issued to an unrelated third party in September 2017 was amended in the amount of $ 36,000 6,000 33,000 3,000 7,000 5,000 6,500 1,000 29,500 1,500 1,500 30,000 0.01 12% 1,000 ● During January 2020, a promissory note originally issued to an unrelated third party in October 2017 in the amount of $ 60,000 76,076 12,149 2.0% 148,225 18,701 166,926 2.0% 166,926 18,917 29,072,500 23,258 343,056 319,798 166,926 183,619 16,693 16,693 20,866,250 16,693 73,032 16,693 56,339 166,926 0.002 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 120,000 20,000 50,000 125,000,000 87,500 37,500 36,000,000 10,000,000 32,200 70,000 14,000 84,000 84,000 ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $ 18,000 3,000 18,000 2,000 (3) At December 31, 2021 and 2020, the balance of $ 3,751,760 1,276,902 283,430 101,448 ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $ 500,000 1,000,000 15,000 30,000 8% March 19, 2018 3,000 27,000 11,412 1,000,000 38,412 ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $ 60,000 10,000 60,000 ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $ 618,250 62,950 0.0003 0.001 255,655 62,950 28,421 During February 2019, we issued convertible notes payable of $ 70,000 5,000 0.0005 22,000 38,500 7,550 16,500 1,650 0.001 195,178 123,900 38,500 16,500 Month of Issuance Number of Warrants Fair Value of Warrants Recorded as Debt Discount Month of Expiration December, 2019 44,000,000 $ 7,370 August, 2020 August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022 During May 2019, we restated two convertible notes payable with additional original issue discount of $ 6,400 During November and December 2019, we issued two convertible promissory notes to the unrelated third party for $ 159,500 14,500 0.0002 0.000275 At December 31, 2019, the principal balance of the notes, net of discount of $ 17,370 736,180 17,370 10,000 During the year ended December 31, 2020, we issued convertible notes payable of $ 555,600 53,600 287,400 268,200 0.0002 0.0008 1,000,000 22,000 700 57,500 7,500 71,875,000 0.002 57,500 50,000 7,500 106,032 65,634 At December 31, 2020, the principal balance of the notes, net of discount of $ 101,448 1,276,902 83,720 During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $ 717,667 93,609 864,225 112,725 539,351 70,350 358,800 46,800 0.0003 0.002 228,563 August 29, 2022 During December 2021, in connection with the issuance of three of the above mentioned convertible notes of $ 172,500 22,500 246,428,571 0.002 150,000 22,500 409,374 During March 2021, the remaining balance of promissory note of $ 30,000 0.01 12% 1,000 7,323 22,677 2,677 During March 2021, in connection with the settlement of the $ 6,000 11,000 11,000,000 6,000 104,500 5,000 98,500 8,500 12,000 2,000,000 4,000 15,200 4,500 11,200 During August 2021, the remaining balance of promissory note of $ 166,926 0.002 183,619 16,693 At the date of this report, $ 1,836,904 308,200 283,430 3,751,760 (4) At December 31, 2021 and 2020, the balance of $ 2,855,709 1,832,439 0 22,344 ● The remaining balance of $ 20,000 120,000 20,000 21,183 17,128 84,768 69,433 ● During May 2017, we issued a Convertible Debenture in the amount of $ 64,000 May 4, 2018 20% 12,629 14,833 12,308 70,418 49,875 ● During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on December 31, 2019 was $ 511,319 107,133,333 22,000 10,140 107,817,770 22,000 10,345 509,301 234,417 250,000 1,859,294 1,609,294 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 ● The new note of $ 250,000 8% We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. 286,969 250,000 3,890 521,370 275,000 32,657 946,639 ● During July 2018, we issued a convertible debenture in the amount of $ 50,000 8% We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. 46,734 50,000 33,490 21,490 202,401 146,232 ● During August 2018, we issued a convertible debenture in the amount of $ 20,000 8% We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. 17,829 12,923 11,713 79,815 57,524 ● During January 2019, the principal balance of $ 60,000 75,000 15,900 75,900 75,900 20,000 75,900 100,000,000 20,000 140,000 At December 31, 2021 and 2020, the convertible note payable of $ 55,900 156,000 129,832 ● During February 2019, we issued a convertible promissory note to an unrelated third party in the amount up to $ 1,000,000 paid upon tranches. The note is due two years from the execution and funding of the note per tranche. The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $ 0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. The eight total tranches of the Note in the amount of $ 372,374 and $ 20,199 have been funded during 2019 and 2020, respectively. An additional three tranches of the Note for a total of $ 132,000 have been funded, and repayment of $ 40,480 has been made during year ended December 31, 2021. In connection with issuance of the convertible note, the Noteholder agreed to eliminate two outstanding Notes of $ 27,000 and the accrued interest of $ 11,412 that were held by the Noteholder’s defunct entities. In connection with the issuance of the convertible note payable tranches during the year ended December 31, 2021 and 2020, we recorded a day-one derivative loss of $ 2,042,612 and $ 31,205 . During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock satisfying the principal balance of $ 100,000 for a fair value of $ 275,000 . During January 2020 through February 2020, the Note holder received a total of 500,000,000 shares of our restricted common stock in satisfaction the $ 175,000 of the Note with a fair value of $ 425,000 . During February through June 2021, the Note holder received a total of 240,350,000 shares of our restricted common stock in satisfaction the $ 120,175 of the Note with a fair value of $ 2,344,399 (See Note 7). The remaining balance of $ 88,917 is due September 2023. At December 31, 2021 and 2020, the convertible note payable with principal balance of $ 88,917 and $ 117,572 , at fair value, was recorded at $ 355,668 and $ 282,173 . Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 ● During June 2019, we issued a convertible promissory note to an unrelated third party for $ 240,000 40,000 16,000,000 4,688 0.0005 240,000 22,344 240,000 960,000 576,000 (5) At December 31, 2021 and 2020, the balance of $ 225,000 (6) During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $ 64,895 1% 24 During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $ 150,000 3.75% 24 731 5,000 8,906 3,660 At December 31, 2021, the future minimum principal payments for the EIDL loan is as follows: SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022 $ 2,121 2023 3,283 2024 3,408 2025 3,538 2026 3,673 Thereafter 133,877 Total $ 149,900 Less: Long-term portion - SBA notes payable (147,779 ) Current portion $ 2,121

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	7 . STOCKHOLDERS’ DEFICIT Authorized Shares On November 18, 2021, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 8,000,000,000 12,000,000,000 Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 1. The Series A Preferred voted with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred was not entitled to dividends unless the Company paid cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred was entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred would have the same record and payment date and terms as the dividend payable on the common stock. 3. The Series A Preferred did not have any redemption rights. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock. Upon return of 100% of Series A Preferred Stock to the Company, the entire class of Series A Preferred Stock was cancelled and the associated Certificate of Determination was filed with the Secretary of State of California. Series B Preferred Stock Effective March 2021, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination for its Series B Preferred Stock. The Series B Preferred Stock has a par value of $ 0.001 per shares and consists of 12,000,000 shares. Terms of the Series B Preferred include the following: 1. The Series B Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series B Preferred is entitled to one thousand votes per share. 2. The Series B Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series B Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series B Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series B Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $ 0.133 4. The Series B Preferred does not have any redemption rights. During November 2021, the Board of Directors approved resolutions for the issuance of a total of 9,000,000 shares of Series B Preferred stock to Mr. Deitsch to discharge $ 540,000 of his accrued salary. The shares were valued at the accrued payable amount by agreement of the parties. Effective November 15, 2021, the Board of Directors authorized an exchange of 3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch for an equal number of Series B Preferred Stock. Settlement of accrued interest of a related-party Note During October 2021, we issued 12,500,000 shares of common stock to satisfy the $ 10,000 accrued interest of a related-party note of $ 200,000 originated in 2010. The shares were valued at the accrued payable amount by agreement of the parties. Common Stock Issued for Conversion of Convertible Debt During February through June 2021, the Note holder received a total of 240,350,000 120,175 2,344,399 SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 During January 2020 through February 2020, the Note holder made conversions of a total of 500,000,000 175,000 Number of Fair Value of Date shares Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes prior to the following conversions was $ 511,319 . During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $ 22,000 and accrued interest of $ 10,140 . During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $ 22,000 and accrued interest of $ 10,345 . Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691 During November 2020, the Note holder assigned $ 20,000 75,900 100,000,000 20,000 140,000 Common Stock Issued for Debt Modification and Penalty During January 2021, we issued a total of 25,000,000 166,926 107,500 During January 2020, we issued a total of 75,000,000 45,000 During March 2020, $ 50,000 120,000 20,000 125,000,000 36,000,000 10,000,000 119,700 During June 2020, we issued 5,000,000 14,400 3,000 During July 2020, we issued a total of 1,000,000 22,000 700 During September 2020, we issued a total of 10,000,000 333,543 6,000 During October 2020, we issued a total of 1,500,000 84,000 900 Common Stock Issued for Settlement of Debt During February 2021, we issued 29,072,500 23,258 166,926 343,056 319,798 During March 2021, in connection with the settlement of a Note of $ 11,000 11,000,000 6,000 104,500 5,000 98,500 During April 2021, in connection with the settlement of the remaining balance of $ 8,500 12,000 2,000,000 4,000 15,200 11,200 During August 2021, in connection with the settlement of $ 16,693 183,619 20,866,250 73,032 56,339 Common Stock Issued for Services During June 2021, the Company signed an agreement with a consultant for services for six months for which the Company is to issue a total of 30,000,000 5,000,000 25,000,000 5,000,000 33,000 25,000,000 100,000 133,000 During July 2021, the Company signed an agreement with a consultant for services for twelve months. The 5,000,000 41,000 20,500 20,500 During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 24,000 15,000,000 6,000 8,500

STOCK WARRANTS

STOCK WARRANTS	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK WARRANTS	8. STOCK WARRANTS Common Stock Warrants On March 31, 2017, in connection with the issuance of an $ 80,000 three 6,000,000 0.005 March 30, 2020 On March 3, 2016, in connection with the issuance of a convertible note, we granted five 2,500,000 0.03 0 9 March 3, 2021 During December 2019, the Company granted 44,000,000 0.001 22,000 7,370 During August 2020, convertible promissory notes of $ 38,500 were amended with additional original issuance discount of $ 7,550 due February 2021. These notes were further amended to due August 2022 on January 1, 2022. During October 2020, a convertible promissory note of $ 16,500 was amended to add additional OID of $ 1,650 due October 2022. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $ 0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. The Company classified embedded conversion features in the warrants as a derivative liability. The warrants were valued at their fair value of $ 195,178 and $ 123,900 on December 31, 2021 and 2020 (see Note 6). SCHEDULE OF WARRANTS ISSUED Fair Value of Month of Issuance Number of Warrants Month of August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022 During November and December, 2020, the Company granted the 71,875,000 0.002 57,500 7,500 57,500 106,032 65,634 During December 2021, in connection with the issuance of three of the convertible notes of $ 172,500 22,500 246,428,571 0.002 409,374 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2021 and 2020: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0018 Expired (166,475,000 ) 0.0019 Balance December 31, 2021 446,703,571 $ 0.0017 The following table summarizes information about fixed-price warrants outstanding as of December 31, 2021 and 2020 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001 0.03 202,775,000 0.93 years $ 0.0017 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017 At December 31, 2021, the aggregate intrinsic value of all warrants outstanding and expected to vest was $ 128,400 0.002 128,400,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	9. INCOME TAXES The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2021 and 2020, are approximately as follows. SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ - SCHEDULE OF DEFERRED INCOME TAX ASSETS 2021 2020 Net deferred income tax assets: Reserve for prepaid inventory $ 12,166 $ 23,573 Accrued salary 267,058 362,356 Recovery for receivables from officer - (25,979 ) Net operating loss carryforwards 10,345,757 9,729,342 Valuation allowance (10,624,981 ) (10,089,292 ) Net deferred income tax asset $ - $ - Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, we have provided a valuation allowance to fully reserve such assets. The valuation allowances increased by $ 535,690 and $ 340,617 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company has net operating loss of approximately $ 40.8 million as of December 31, 2021, of which $ 6.0 million were incurred after December 31, 2017 that are available to offset future taxable income with no expiration date. The remaining approximately $ 34.8 million of net operating losses expire between 2023 and 2037. The Company’s 2018 through 2021 tax returns are subject to examination by the Internal Revenue Services and various state authorities.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES	10. ACCRUED EXPENSES Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES December 31, 2021 2020 Accrued consulting fees $ 161,550 $ 166,900 Accrued settlement expenses - 35,000 Accrued payroll taxes 215,543 215,581 Accrued interest 469,040 351,830 Accrued others 5,337 11,121 Total $ 851,470 $ 780,432

PREPAID EXPENSES

PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses
PREPAID EXPENSES	11. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES December 31, December 31, Supplier advances for future purchases $ 294,162 $ 246,162 Reserve for supplier advances (294,162 ) (246,162 ) Net supplier advances - - Prepaid professional fees 65,650 10,000 Deferred stock compensation 20,500 - Total $ 86,150 $ 10,000 We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases by $ 48,000 21,303 294,162 246,162

CONVERTIBLE NOTES RECEIVABLE

CONVERTIBLE NOTES RECEIVABLE	12 Months Ended
	Dec. 31, 2021
Convertible Notes Receivable
CONVERTIBLE NOTES RECEIVABLE	12. CONVERTIBLE NOTES RECEIVABLE During March through November 2021, we purchased five convertible notes from an unrelated third party (the “Third Party”) for a total of $ 286,550 with original issuance discount of $ 26,050 . The notes are convertible into common shares for $ 0.01 per common share and matures in one year from the funding of the Notes. The original issuance discount is amortized over the lives of notes. The debt discount as of December 31, 2021 was $ 13,070 . Amortization for all the convertible notes receivable was $ 12,980 recognized as other income in the statement of operations for the year ended December 31, 2021. $ 26,950 of the Notes expired on March 10, 2022. We are working on restructuring and converting the Notes into common stock of the Third Party.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	13. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into a three-year operating lease for monthly payments of approximately $ 3,200 the lease on a month-to-month basis until May 2020 when it was terminated ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $ 6,900 The lease calls for monthly payments of approximately $ 6,500 SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION December 31, December 31, 2021 2020 Lease cost Operating lease cost $ 80,396 $ 89,021 Short-term lease cost - 18,698 Total lease cost $ 80,396 $ 107,719 Balance sheet information Operating ROU Assets $ 93,811 $ 144,010 Operating lease obligations, current portion 77,673 82,873 Operating lease obligations, non-current portion - 60,447 Total operating lease obligations $ 77,673 $ 143,320 Weighted average remaining lease term (in years) – operating leases 1 1.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2021 and 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 95,846 $ 98,780 Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years 500,000 8 50,000 0.18 142,500 During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 3,000 31,750 1,000,000 19,150 1,500,000 Litigation Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and ReceptoPharm to recover $ 315,000 On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $ 100,000 101,818 21,023 104,000 CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $ 100,000 91,156 51,856 Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. At this time, the Court has not ruled on the pending Motion. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS Convertible Notes Payable Pursuant to the Note agreement in the amount up to $ 1,000,000 signed in February 2019, As of December 31, 2021, the remaining balance of $ 88,917 is due September 2023. During February 2022, the Note holder made a conversion of 12,000,000 shares of stock satisfying the principal balance of $ 6,000 for a fair value of $ 36,000 . During the first quarter of 2022, we issued convertible promissory notes to the unrelated third parties for a total of $ 225,000 75,000 0.0005 0.0008 Restatement of Promissory Notes During February 2022, the restated Note of $ 183,619 16,693 20,866,250 16,693 54,252 37,559 183,619 16,693 Promissory Notes During January 2022, the Company received a loan for a total of $ 199,000 63.76 4,975

BASIS OF PRESENTATION AND SUM_2

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Organization	Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Luxury Feet, an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or discomfort due to high heels and stilettos. In October of 2021 we began manufacturing a zeolite detoxifier called Cell Defender for a third party distributor.
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation.
Liquidity and Going Concern	Liquidity and Going Concern Our Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $ 81,728,989 20,606,665 20,877,650 There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Impact of COVID-19 on our Operations	Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from the Small Business Administration (“SBA”) to fund our request for a PPP loan for $ 64,895 150,000 The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine.
Use of Estimates	Use of Estimates The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known.
Revenue from Contracts with Customers	Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor.
Accounting for Shipping and Handling Costs	Accounting for Shipping and Handling Costs We account for shipping and handling as fulfilment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No
Inventories	Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at December 31, 2021 and 2020, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $ 48,000 21,303 294,162 246,162
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the year ended December 31, 2021, there was one customer that accounted for 21 37 100
Operating Lease Right-of-Use Asset and Liability	Operating Lease Right-of-Use Asset and Liability The Company accounts for leases in accordance with Accounting Standards Update (“ASU”) 2016-02, Leases In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate.
Derivative Financial Instruments	Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Convertible Debt	Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note.
The Fair Value Measurement Option	The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging
Derivative Accounting for Convertible Debt and Options and Warrants	Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC 815, Derivatives and Hedging Embedded Derivatives
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 7
Long-Lived Assets	Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.
Income Taxes	Income Taxes We compute income taxes in accordance with FASB ASC Topic 740, Income Taxes On an annual basis, we evaluate tax positions that have been taken or are expected to be taken in our tax returns to determine if they are more than likely to be sustained if the taxing authority examines the respective position. At December 31, 2021 and 2020, we do not believe we have a need to record any liabilities for uncertain tax positions or provisions for interest or penalties related to such positions.
Stock-Based Compensation	Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation
Net Loss Per Share	Net Loss Per Share Net loss per share is calculated in accordance with ASC Topic 260, Earnings per Share SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modification or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”), which will clarify and reduce diversity in practice. Specifically, the new standard includes a recognition model comprising four categories of transactions and corresponding accounting treatment for each category. The category that would apply to a modification or an exchange of an equity-classified warrant would depend on the substance of the modification transaction (e.g. a financing transaction to raise equity versus one to raise debt). This recognition model is premised on the idea that the accounting for the transaction should not differ from what it would have been had the issuer of the warrants paid cash instead of modifying the warrants. ASU 2021-04 will be effective for fiscal years beginning after December 15, 2021 and interim periods within those fiscal years. This ASU will be applied prospectively to modifications or exchanges occurring on or after the effective date of the ASU. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

BASIS OF PRESENTATION AND SUM_3

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE	SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE 31-Dec-21 31-Dec-20 Options and warrants 446,703,571 202,775,000 Convertible notes payable at fair value 1,427,853,386 1,515,706,865 Convertible notes payable 4,913,379,125 2,814,694,508 Total 6,787,936,082 4,533,176,373

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2021
Short-term Debt [Line Items]
SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE	The following table summarizes our financial instruments measured at fair value at December 31, 2021 and December 31, 2020: SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE Fair Value Measurements at December 31, 2021 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 710,585 $ - $ - $ 710,585 Derivative liabilities $ 9,826,759 $ - $ 9,826,759 $ - Convertible notes at fair value $ 2,855,709 $ - $ - $ 2,855,709 Fair Value Measurements at December 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 189,543 $ - $ - $ 189,543 Derivative liabilities $ 3,377,633 $ - $ 3,377,633 $ - Convertible notes at fair value $ 1,832,439 $ - $ - $ 1,832,439
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS	The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the years ended December 31, 2021 and 2020: SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 189,543 $ 1,411 Purchases, issuances, and settlements 590,885 143,369 Total loss (gain) included in earnings (1) (69,843 ) 44,763 Total loss (gain) included in earnings (69,843 ) 44,763 Ending balance $ 710,885 $ 189,543 (1) The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS	The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at December 31, 2021 and 2020: SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back 2021 $ 762,446 8 10 20 24 N/A $ 0.00050 0.00097 50 60 3 25 2020 $ 766,101 8 10 20 24 N/A $ 0.00050 0.00064 50 60 3 25
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS	SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS Description 2021 2020 Beginning balance $ 1,832,439 $ 5,814,047 Purchases and issuances 132,000 25,981 Day one loss on value of hybrid instrument (1) 2,042,612 318,174 Day one loss on value of hybrid instrument 2,042,612 318,174 Loss (gain) from change in fair value (1) 1,233,538 (1,931,927 Loss (gain) from change in fair value 1,233,538 (1,931,927 Gain on settlement - (1,609,294 Debt discount - 22,344 Repayments in cash (40,480 ) (5,782 ) Conversion to common stock (2,344,399 ) (801,104 ) Ending balance $ 2,855,709 $ 1,832,439 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories are valued at the lower of cost or net realizable value on an average cost basis. At December 31, 2021 and 2020, inventories were as follows: SCHEDULE OF INVENTORIES December 31, 2021 December 31, 2020 Raw Materials $ 126,349 $ 78,880 Finished Goods 3,820 5,271 Total Inventories 130,169 84,151 Less: Long-term inventory (98,880 ) (78,880 ) Current portion $ 31,289 $ 5,271

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment consists of the following at December 31, 2021 and 2020: SCHEDULE OF PROPERTY AND EQUIPMENT December 31, December 31, Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 104,564 65,521 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 266,886 227,843 Less: Accumulated depreciation (222,185 ) (213,101 ) Property and equipment, net $ 44,701 $ 14,742

DEBTS (Tables)

DEBTS (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
SCHEDULE OF DEBT	Debts consist of the following at December 31, 2021 and 2020: SCHEDULE OF DEBT December 31, 2021 December 31, 2020 Notes payable – Unrelated third parties (Net of discount of $ 0 1,500 $ 1,135,257 $ 1,346,057 Convertible notes payable – Unrelated third parties (Net of discount of $ 283,429 101,448 3,751,760 1,276,902 Convertible notes payable, at fair value (4) 2,855,709 1,832,439 Other advances from an unrelated third party (5) 225,000 225,000 SBA notes payable(6) 149,900 214,795 Ending balances 8,117,626 4,895,193 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (369,401 ) (48,477 ) Less: Long-term portion- SBA notes payable (147,779 ) (204,070 ) Current portion $ 7,600,446 $ 4,642,646
SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT	SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT Years Amount 2022 $ 2,121 2023 3,283 2024 3,408 2025 3,538 2026 3,673 Thereafter 133,877 Total $ 149,900 Less: Long-term portion - SBA notes payable (147,779 ) Current portion $ 2,121

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT	SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 Number of Fair Value of Date shares Debt 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Number of Fair Value of Date shares converted Debt 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 $ 64,691

STOCK WARRANTS (Tables)

STOCK WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
SCHEDULE OF WARRANTS ISSUED	SCHEDULE OF WARRANTS ISSUED Fair Value of Month of Issuance Number of Warrants Month of August, 2020 92,100,000 $ 38,500 August, 2022 October, 2020 36,300,000 $ 16,500 October, 2022
SUMMARY OF WARRANTS OUTSTANDING	A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the years ended December 31, 2021 and 2020: SUMMARY OF WARRANTS OUTSTANDING Number Of Weighted Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued 200,275,000 0.0014 Expired (50,000,000 ) 0.0015 Balance December 31, 2020 202,775,000 $ 0.0017 Exercised - - Issued 410,403,571 0.0018 Expired (166,475,000 ) 0.0019 Balance December 31, 2021 446,703,571 $ 0.0017
SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING	The following table summarizes information about fixed-price warrants outstanding as of December 31, 2021 and 2020 : SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING Exercise Price Weighted Average Number Outstanding Weighted Weighted 2020 $ 0.001 0.03 202,775,000 0.93 years $ 0.0017 2021 $ 0.001 0.002 446,703,571 0.67 $ 0.0017

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX EXPENSE	The Company’s tax expense differs from the “expected” tax expense for the years ended December 31, 2021 and 2020, are approximately as follows. SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ -
SCHEDULE OF INCOME TAX EXPENSE	SCHEDULE OF INCOME TAX EXPENSE December 31, 2021 2020 Computed “expected” tax expense (benefit) - Federal $ (2,750,059 ) (161,529 ) Computed “expected” tax expense (benefit) - State (569,000 ) (33,421 ) Permanent differences and other 2,783,369 (145,667 Change in valuation allowance 535,690 340,617 Provision for income taxes $ - $ -
SCHEDULE OF DEFERRED INCOME TAX ASSETS	SCHEDULE OF DEFERRED INCOME TAX ASSETS 2021 2020 Net deferred income tax assets: Reserve for prepaid inventory $ 12,166 $ 23,573 Accrued salary 267,058 362,356 Recovery for receivables from officer - (25,979 ) Net operating loss carryforwards 10,345,757 9,729,342 Valuation allowance (10,624,981 ) (10,089,292 ) Net deferred income tax asset $ - $ -

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consisted of the following: SCHEDULE OF ACCRUED EXPENSES December 31, 2021 2020 Accrued consulting fees $ 161,550 $ 166,900 Accrued settlement expenses - 35,000 Accrued payroll taxes 215,543 215,581 Accrued interest 469,040 351,830 Accrued others 5,337 11,121 Total $ 851,470 $ 780,432

PREPAID EXPENSES (Tables)

PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2021
Prepaid Expenses
SCHEDULE OF PREPAID EXPENSES	Prepaid expenses and other current assets consist of the following: SCHEDULE OF PREPAID EXPENSES December 31, December 31, Supplier advances for future purchases $ 294,162 $ 246,162 Reserve for supplier advances (294,162 ) (246,162 ) Net supplier advances - - Prepaid professional fees 65,650 10,000 Deferred stock compensation 20,500 - Total $ 86,150 $ 10,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE	SCHEDULE OF LEASE COST AND BALANCE SHEET INFORMATION December 31, December 31, 2021 2020 Lease cost Operating lease cost $ 80,396 $ 89,021 Short-term lease cost - 18,698 Total lease cost $ 80,396 $ 107,719 Balance sheet information Operating ROU Assets $ 93,811 $ 144,010 Operating lease obligations, current portion 77,673 82,873 Operating lease obligations, non-current portion - 60,447 Total operating lease obligations $ 77,673 $ 143,320 Weighted average remaining lease term (in years) – operating leases 1 1.67 Weighted average discount rate-operating leases 8 % 8 % Supplemental cash flow information related to leases were as follows, for the years ended December 31, 2021 and 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 95,846 $ 98,780 Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673
SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE	Future minimum payments under the lease agreement are as follows: SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE December 31, Total 2022 $ 81,080 Total future lease payments $ 81,080 Less imputed interest 3,407 Total $ 77,673

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	6,787,936,082	4,533,176,373
Option and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	446,703,571	202,775,000
Convertible Notes Payable Fair Value [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,427,853,386	1,515,706,865
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	4,913,379,125	2,814,694,508

BASIS OF PRESENTATION AND SUM_4

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	May 31, 2020	Apr. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Product Information [Line Items]
Retained earnings			$ 81,728,989	$ 68,633,468
Working capital deficit			20,606,665
Stockholders' equity			20,877,650	11,493,815	$ 11,701,035
Allowance for doubtful account			0	0
Change in reserve for supplier advances for purchases			48,000	21,303
Inventory valuation allowance			$ 294,162	$ 246,162
Minimum [Member]
Product Information [Line Items]
Property and equipment estimated useful lives			3 years
Maximum [Member]
Product Information [Line Items]
Property and equipment estimated useful lives			7 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage			21.00%	37.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage			100.00%	100.00%
SBA Loan Agreement [Member]
Product Information [Line Items]
Proceeds form loan	$ 64,895	$ 150,000

SUMMARY OF FINANCIAL INSTRUMENT

SUMMARY OF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 710,585	$ 189,543
Derivative liabilities	9,826,759	3,377,633
Convertible notes at fair value	2,855,709	1,832,439
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Derivative liabilities
Convertible notes at fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Derivative liabilities	9,826,759	3,377,633
Convertible notes at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	710,585	189,543
Derivative liabilities
Convertible notes at fair value	$ 2,855,709	$ 1,832,439

SUMMARY OF CHANGES IN FAIR VALU

SUMMARY OF CHANGES IN FAIR VALUE MEASUREMENTS USING SIGNIFICANT UNOBSERVABLE INPUTS (Details) - USD ($)		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Convertible Notes Payable [Member]
Purchases and issuances		$ 132,000	$ 25,981
Beginning balance		1,832,439	5,814,047
Day one loss on value of hybrid instrument	[1]	2,042,612	318,174
Loss (gain) from change in fair value	[1]	1,233,538	(1,931,927)
Gain on settlement			(1,609,294)
Debt discount			22,344
Repayments in cash		(40,480)	(5,782)
Conversion to common stock		(2,344,399)	(801,104)
Ending balance		2,855,709	1,832,439
Warrant [Member]
Beginning balance		189,543	1,411
Purchases and issuances		590,885	143,369
Total loss (gain) included in earnings	[2]	(69,843)	44,763
Ending balance		$ 710,885	$ 189,543
[1]	The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.
[2]	The loss (gain) related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations.

SUMMARY OF ASSUMPTIONS AND THE

SUMMARY OF ASSUMPTIONS AND THE SIGNIFICANT TERMS (Details) - Convertible Notes Payable [Member]	12 Months Ended
	Dec. 31, 2021USD ($)Day$ / shares	Dec. 31, 2020USD ($)Day$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Face Amount | $	$ 762,446	$ 766,101
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Conversion Price | $ / shares	$ 0.00050	$ 0.00050
Percentage of stock price for look-back period	50.00%	50.00%
Look-back period | Day	3	3
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Conversion Price | $ / shares	$ 0.00097	$ 0.00064
Percentage of stock price for look-back period	60.00%	60.00%
Look-back period | Day	25	25
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	8	8
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	10	10
Measurement Input, Default Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	20	20
Measurement Input, Default Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Long-term debt, measurement input	24	24

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative)	Dec. 31, 2021
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding measurement input, percentage	0.19
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding measurement input, percentage	0.39
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding measurement input, percentage	273
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding measurement input, percentage	276
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding measurement input, percentage	0

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw Materials	$ 126,349	$ 78,880
Finished Goods	3,820	5,271
Total Inventories	130,169	84,151
Less: Long-term inventory	(98,880)	(78,880)
Current portion	$ 31,289	$ 5,271

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total	$ 266,886	$ 227,843
Less: Accumulated depreciation	(222,185)	(213,101)
Property and equipment, net	44,701	14,742
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	25,120	25,120
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	34,757	34,757
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	104,564	65,521
Telephone Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	12,421	12,421
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	16,856	16,856
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 73,168	$ 73,168

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization, Nonproduction	$ 9,084	$ 3,831

DUE TO_FROM OFFICER (Details Na

DUE TO/FROM OFFICER (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Due to officer	$ 199,726	$ 200,837
Repayment of officers loans	182,741	22,150
Loans from officer	105,780	254,000
Accrued interest expense for amount due to officer	7,520	7,675
Rik Deitsch [Member]
Related Party Transaction [Line Items]
Due to officer	$ 199,726	$ 200,837
Debt Instrument, Interest Rate, Stated Percentage	4.00%	4.00%
Repayment of officers loans	$ 182,741	$ 22,150
Loans from officer	105,780	254,000
Accrued interest expense for amount due to officer	7,520	7,675
Bad debt expense	$ 68,330	161,500
Company other receivable reserves		$ 402,970

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes payable – Unrelated third parties (Net of discount of $0 and $1,500, respectively) (2)	$ 1,135,257	$ 1,346,057
Convertible notes payable – Unrelated third parties (Net of discount of $283,429 and $101,448, respectively) (3)	3,751,760	1,276,902
Convertible notes payable, at fair value (4)	2,855,709	1,832,439
Other advances from an unrelated third party (5)	225,000	225,000
SBA notes payable(6)	149,900	214,795
Ending balances	8,117,626	4,895,193
Less: Long-term portion-Convertible Notes payable-Unrelated third parties	(369,401)	(48,477)
Less: Long-term portion- SBA notes payable	(147,779)	(204,070)
Current portion	$ 7,600,446	$ 4,642,646

SCHEDULE OF DEBT (Details) (Par

SCHEDULE OF DEBT (Details) (Parenthetical) - USD ($)	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Apr. 30, 2017	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Fair Value Adjustment of Warrants										$ 16,500	$ 38,500
Conversion of shares, shares	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000	107,817,770	107,133,333	250,000,000	250,000,000
Conversion of shares, amount	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930	$ 64,691	$ 171,413	$ 275,000	$ 150,000
Convertible Notes Payable [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt discount										$ 1,650	$ 7,550
Number of Warrants										36,300,000	92,100,000	44,000,000
Fair Value Adjustment of Warrants										$ 16,500	$ 38,500	$ 7,370		$ 195,178	$ 123,900
Warrants and Rights Outstanding, Maturity Date										October, 2022	August, 2022	August, 2020
Note Payable [Member]
Short-term Debt [Line Items]
Debt discount														0	1,500
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt discount														$ 283,429	$ 101,448
Conversion of shares, shares	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000	107,817,770	107,133,333
Conversion of shares, amount	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930	$ 64,691	$ 171,413
Promissory Note Two [Member]
Short-term Debt [Line Items]
Repayments of notes payable													$ 25,000

SCHEDULE OF FUTURE MINIMUM PRIN

SCHEDULE OF FUTURE MINIMUM PRINCIPAL PAYMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Current portion	$ 7,600,446	$ 4,642,646
Economic Injury Disaster Loan [Member]
Short-term Debt [Line Items]
2022	2,121
2023	3,283
2024	3,408
2025	3,538
2026	3,673
Thereafter	133,877
Total	149,900
Less: Long-term portion - SBA notes payable	(147,779)
Current portion	$ 2,121

DEBTS (Details Narrative)

DEBTS (Details Narrative) - USD ($)	Jan. 02, 2022	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 22, 2020	Oct. 05, 2020	Sep. 21, 2020	Mar. 31, 2020	Feb. 18, 2020	Jan. 21, 2020	Feb. 15, 2019	Sep. 26, 2016	Mar. 19, 2014	Aug. 02, 2011	Oct. 31, 2021	Aug. 31, 2021	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Nov. 30, 2020	Oct. 31, 2020	Oct. 30, 2020	Sep. 30, 2020	Aug. 31, 2020	Jul. 31, 2020	Jun. 30, 2020	May 31, 2020	Mar. 31, 2020	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Nov. 30, 2019	Sep. 30, 2019	Jun. 30, 2019	Feb. 28, 2019	Jan. 31, 2019	Sep. 30, 2018	Aug. 31, 2018	Jul. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Nov. 30, 2017	Oct. 31, 2017	Jul. 31, 2017	Jun. 30, 2017	May 31, 2017	Apr. 30, 2017	Oct. 31, 2016	Aug. 31, 2016	Jul. 31, 2016	Jun. 30, 2016	May 31, 2016	Apr. 30, 2016	Jun. 30, 2012	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2014	Mar. 31, 2012	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2012	Dec. 31, 2010	Sep. 30, 2023	Aug. 31, 2022	Feb. 28, 2022	May 31, 2019	Mar. 31, 2016	Aug. 31, 2013	Dec. 31, 2011
Short-term Debt [Line Items]
Principal balance																																																																					$ 101,818
Accrued interest																	$ 10,000																																															$ 147,768		$ 147,768	$ 179,522
Notes payable																																																																1,135,257		1,135,257	1,346,057
Shares issued, amount																	200,000
Accrued interest																																																																					21,023
Amortization of debt																																																																		326,391	130,485
Debt conversion, amount		$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930		$ 64,691	$ 171,413		$ 275,000	$ 150,000
Debt conversion, shares issued		2,500,000	5,700,000	27,070,000	67,380,000	137,700,000		107,817,770	107,133,333		250,000,000	250,000,000
Convertible notes payable - Unrelated third parties																																																																3,751,760		3,751,760	1,276,902
Proceeds from convertible debt																																																																		2,288,560	527,983
Warrants, fair value																								$ 16,500			$ 38,500
Repayments of convertible debt																																																																		67,302	5,782
Stock issued																																																																		2,344,399	801,104
Convertible Debt, Fair Value Disclosures																																																																2,855,709		2,855,709	1,832,439
Proceeds from related party																																																																		105,780	254,000
University Centre West Ltd [Member]
Short-term Debt [Line Items]
Payments for rent																																																																						$ 55,410
Note Payable [Member]
Short-term Debt [Line Items]
Debt discount																																																																0		0	1,500
Promissory Note One [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																								10.00%
Accrued interest																																																																5,783		5,783	4,769
Proceeds from debt																																																								$ 10,000
Promissory Note Two [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																							2.00%
Accrued interest																																																																74,334		74,334	62,167
Notes payable																																																																50,000		50,000	50,000
Proceeds from debt																																																							$ 75,000
Promissory Note Two [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Shares issued, shares																																																		5,000,000
Promissory Note Three [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																						2.00%
Accrued interest																																																																67,534		67,534	55,367
Notes payable																																																																50,000		50,000	50,000
Proceeds from debt																																																						$ 50,000
Promissory Note Four [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																				2.00%
Notes payable																																																																333,543		333,543	333,543
Proceeds from debt																																																				$ 333,543
Accrued interest																																																																187,673		187,673	167,216
Promissory Note Four [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Shares issued, shares																																																				20,000,000
Debt discount																																																																			$ 5,895
Stock issued, reverse stock splits																																																																			10,000,000
Shares issued, amount																																																																			$ 6,000
Promissory Note Five [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate														10.00%
Accrued interest																																	$ 15,900																															1,371		1,371	1,371
Notes payable																																	60,000																															15,000		15,000	15,000
Proceeds from debt														$ 75,000
Debt settlement amount																																												$ 15,000
Promissory Note Six [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																			2.00%
Accrued interest																																																																63,834		63,834	51,667
Proceeds from debt																																																			$ 50,000
Promissory Note Seven [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																																10.00%
Accrued interest																																																																5,750		5,750	4,483
Proceeds from debt																																																$ 12,500
Promissory Note Eight [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																																															15.00%
Notes payable																																																																33,874		33,874	48,250
Proceeds from debt																																															$ 200,000
Debt settlement amount																																																																		33,874
Repayment of debt settlement amount																																																										$ 130,401
Repayments of debt																																																										14,376									44,478	$ 42,698	34,976
Promissory Note Eight [Member] | One Unrelated Third Parties [Member]
Short-term Debt [Line Items]
Debt settlement amount																																											$ 130,401
Repayments of debt																																											5,000
Promissory Note Eight [Member] | Two Unrelated Third Parties [Member]
Short-term Debt [Line Items]
Debt settlement amount																																											40,000
Repayments of debt																																											$ 2,000
Promissory Note Nine [Member]
Short-term Debt [Line Items]
Notes payable																																																																$ 50,000		$ 50,000	50,000
Debt discount																																															10,000
Proceeds from debt																																															$ 50,000
Promissory Note Ten [Member]
Short-term Debt [Line Items]
Principal balance																										$ 33,000																																									29,500
Debt instrument, interest rate																																																																12.00%		12.00%
Debt discount																										6,000										$ 6,000																															1,500
Proceeds from debt																																				$ 36,000				$ 36,000
Repayments of debt																																																										1,000									6,500	5,000	7,000
Debt instrument, periodic payment																																																																		$ 1,000
Debt discount																										3,000
Amortization of debt																																																										1,500
Debt conversion, amount																																																										$ 30,000
Debt conversion price																					$ 0.01																																					$ 0.01
Promissory Note Eleven [Member]
Short-term Debt [Line Items]
Principal balance																		$ 16,693				$ 166,926											$ 166,926
Debt instrument, interest rate																												2.00%
Accrued interest																						23,258						$ 18,701																									$ 12,149														18,917
Notes payable																		166,926				183,619																																													166,926
Debt discount																						16,693
Proceeds from debt																												148,225																		$ 60,000							$ 76,076
Debt fair value																		73,032				343,056
Debt settlement amount																		16,693
Amortization of debt																		$ 16,693
Debt conversion price																		$ 0.002
Debt instrument interest rate, during period																																	2.00%
Gain on settlement of debt																		$ 56,339				$ 319,798
Promissory Note Eleven [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Shares issued, shares																		20,866,250				29,072,500
Promissory Note Twelve [Member]
Short-term Debt [Line Items]
Shares issued, shares																															125,000,000														10,000,000
Notes payable																										84,000																			$ 70,000																			$ 84,000		84,000	84,000
Debt discount																																													20,000
Proceeds from debt																																													120,000
Debt settlement amount										$ 50,000
Shares issued, amount																															$ 87,500														32,200
Debt discount																																													$ 14,000
Gain on settlement of debt																															$ 37,500
Debt conversion, shares issued																																													36,000,000
Promissory Note Thirteen [Member]
Short-term Debt [Line Items]
Accrued interest																																																																2,000		2,000	2,000
Notes payable																																																																18,000		18,000	18,000
Debt discount																																													$ 3,000
Proceeds from debt																																													$ 18,000
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Principal balance																																																																3,751,760		3,751,760
Debt discount																																																																283,429		283,429	101,448
Debt discount																																																																283,430		283,430	101,448
Amortization of debt																																																																		308,200
Debt conversion, amount		$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930		$ 64,691	$ 171,413
Debt conversion, shares issued		2,500,000	5,700,000	27,070,000	67,380,000	137,700,000		107,817,770	107,133,333
Total, debt discount																																																																283,430		283,430
Convertible notes payable																																																																1,836,904		1,836,904
Two Convertible Debentures [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate															8.00%
Debt instrument, maturity date															Mar. 19, 2018
Accrued interest																																																																					11,412
Notes payable																																																																					27,000
Debt fair value															$ 1,000,000																																													$ 30,000
Repayments of debt																																																																					3,000
Gain on settlement of debt																																$ 38,412
Proceeds from convertible debt															$ 500,000																	$ 1,000,000																												$ 15,000
Promissory Note [Member]
Short-term Debt [Line Items]
Shares issued, shares																		20,866,250		2,000,000	11,000,000	29,072,500
Notes payable																		$ 183,619		$ 4,000	$ 6,000	$ 166,926																																				$ 6,000						60,000		60,000	60,000
Debt discount																		16,693		12,000	11,000																									10,000												11,000
Proceeds from debt																																														$ 60,000
Shares issued, amount																		73,032		15,200	104,500	343,056
Accrued interest																						$ 23,258
Convertible Notes Payable One [Member]
Short-term Debt [Line Items]
Debt discount																								1,650			7,550							$ 62,950				$ 5,000																														62,950	62,950
Amortization of debt																																																																				28,421
Proceeds from convertible debt																																						$ 70,000																														22,000	$ 618,250
Conversion price, decrease																																																																					$ 0.0003
Conversion price, increase																																																																					$ 0.001
Total, debt discount																																																																					$ 255,655
Convertible debt																								16,500			38,500
Convertible Notes Payable One [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt discount																								$ 16,500			$ 38,500
Warrants, exercise price																								$ 0.001
Warrants, fair value																																																																		195,178	123,900
Convertible Notes Payable Two [Member]
Short-term Debt [Line Items]
Notes payable																													$ 268,200																																						287,400
Debt discount																												7,500																																			$ 70,350	50,000		50,000	53,600
Repayments of debt																												22,000
Shares issued, amount																												700
Amortization of debt																																																																			83,720
Debt conversion price																																						$ 0.0005
Proceeds from convertible debt																																																														$ 864,225				358,800	$ 555,600
Conversion price, decrease																																																																			$ 0.0008
Conversion price, increase																																																																			$ 0.0002
Total, debt discount																																																																			$ 1,276,902
Convertible debt																												$ 57,500
Convertible notes payable																																																																			101,448
Convertible Notes Payable Two [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Convertible debt																																																																									$ 57,500
Convertible Notes Payable Two [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt discount																																																																7,500		7,500
Warrants, exercise price																												$ 0.002
Warrants, fair value																																																																		106,032	$ 65,634
Warrants, granted																												71,875,000
Convertible Notes Payable Two [Member] | Restricted Shares [Member]
Short-term Debt [Line Items]
Shares issued, shares																												1,000,000
Two Convertible Notes Payable One [Member]
Short-term Debt [Line Items]
Debt discount																																																																											$ 6,400
Two Convertible Notes Payable Two [Member]
Short-term Debt [Line Items]
Notes payable																																		17,370																																		17,370
Debt discount																																		14,500	$ 14,500																																	14,500
Amortization of debt																																		17,370
Proceeds from convertible debt																																		$ 159,500	$ 159,500
Conversion price, decrease																																		$ 0.000275
Conversion price, increase																																		$ 0.0002
Total, debt discount																																		$ 736,180																																		736,180
Repayments of convertible debt																																		10,000
Convertible Notes Payable Three [Member]
Short-term Debt [Line Items]
Debt discount																			$ 112,725		$ 93,609																																					93,609				112,725		46,800		46,800
Proceeds from convertible debt																																																										$ 717,667					$ 539,351
Conversion price, decrease																																																																			$ 0.0003
Conversion price, increase																																																																			$ 0.002
Convertible Notes Payable Three [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument, maturity date	Aug. 29, 2022
Notes payable	$ 228,563
Convertible Notes Payable Four [Member]
Short-term Debt [Line Items]
Debt discount																																																																22,500		22,500
Proceeds from convertible debt																																																																		172,500
Convertible Notes Payable Four [Member] | Warrant [Member]
Short-term Debt [Line Items]
Debt discount																																																																150,000		150,000
Warrants, exercise price																												$ 0.002
Warrants, fair value																																																																		409,374
Warrants, granted																												246,428,571
Convertible Notes Payable Five [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate																					12.00%																																					12.00%
Shares issued, shares																					2,000,000
Interest expense																																																																		2,677
Notes payable																					$ 30,000																																					$ 30,000						22,677		22,677
Repayments of debt																																																																7,323
Debt instrument, periodic payment																					$ 1,000
Debt conversion price																					$ 0.01																																					$ 0.01
Convertible Notes Payable Six [Member]
Short-term Debt [Line Items]
Shares issued, shares																					11,000,000
Debt fair value																				15,200
Debt settlement amount																				8,500	$ 6,000
Shares issued, amount																					104,500
Gain on settlement of debt																				11,200	98,500
Proceeds from convertible debt																				12,000	11,000
Repayments of convertible debt																				4,500	5,000
Stock issued																				$ 4,000	6,000
Convertible Notes Payable Seven [Member]
Short-term Debt [Line Items]
Notes payable																		$ 166,926
Debt conversion price																		$ 0.002
Convertible Notes Payable Seven [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Notes payable																																																																										$ 183,619
Debt discount																																																																										$ 16,693
Convertible Loans [Member]
Short-term Debt [Line Items]
Debt discount																																																																0		0	$ 22,344
Proceeds from related party																																																																	$ 225,000
Convertible Loans One [Member]
Short-term Debt [Line Items]
Principal balance																																																																20,000		20,000	20,000
Accrued interest																																																																21,183		21,183	17,128
Notes payable																																																																												$ 20,000
Debt fair value																																																																84,768		84,768	69,433
Convertible debt																																																																												$ 120,000
Convertible Loans Two [Member]
Short-term Debt [Line Items]
Principal balance																																																																12,629		12,629	12,629
Debt instrument, interest rate																																																	20.00%
Debt instrument, maturity date																																																	May 4, 2018
Accrued interest																																																																14,833		14,833	12,308
Debt fair value																																																																70,418		70,418	49,875
Proceeds from convertible debt																																																	$ 64,000
Convertible Loans Three [Member]
Short-term Debt [Line Items]
Principal balance							$ 250,000
Accrued interest							234,417
Notes payable							509,301																											$ 511,319																																		511,319
Debt fair value							1,859,294
Gain on settlement of debt							$ 1,609,294
Convertible Loans Three [Member] | Restricted Shares [Member]
Short-term Debt [Line Items]
Accrued interest																								$ 10,345		$ 10,140
Shares issued, shares																									107,817,770	107,133,333
Notes payable																								$ 22,000		$ 22,000
Convertible Loans Four [Member]
Short-term Debt [Line Items]
Principal balance																																																																$ 250,000		$ 250,000
Debt instrument, interest rate terms																																																																		We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date.
Debt instrument, interest rate																																																																8.00%		8.00%
Accrued interest																																																																$ 32,657		$ 32,657	3,890
Notes payable																																																																275,000		275,000	250,000
Debt fair value																																																																946,639		946,639	521,370
Derivative loss																																																																		286,969
Convertible Loans Five [Member]
Short-term Debt [Line Items]
Principal balance																																										$ 50,000
Debt instrument, interest rate terms																																										We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice.
Debt instrument, interest rate																																										8.00%
Accrued interest																																																																33,490		33,490	21,490
Notes payable																																																																50,000		50,000	50,000
Debt fair value																																																																202,401		202,401	146,232
Derivative loss																																										$ 46,734
Convertible Loans Six [Member]
Short-term Debt [Line Items]
Principal balance																																									$ 20,000
Debt instrument, interest rate terms																																									We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice.
Debt instrument, interest rate																																									8.00%
Accrued interest																																																																12,923		12,923	11,713
Notes payable																																																																12,923		12,923	11,713
Debt fair value																																																																79,815		79,815	57,524
Derivative loss																																									$ 17,829
Convertible Loans Seven [Member]
Short-term Debt [Line Items]
Principal balance																							$ 20,000																$ 60,000
Accrued interest																																							15,900
Notes payable																							$ 75,900																75,000
Debt fair value																																							75,900																									156,000		156,000	129,832
Convertible debt																																																																55,900		55,900	55,900
Derivative loss																																							$ 75,900
Convertible Loans Seven [Member] | Restricted Shares [Member]
Short-term Debt [Line Items]
Shares issued, shares																							100,000,000
Debt fair value																							$ 140,000
Stock issued																							20,000
Convertible Loans Eight [Member]
Short-term Debt [Line Items]
Principal balance																																					$ 100,000	$ 1,000,000
Accrued interest																																																																11,412		11,412
Shares issued, shares																			240,350,000													500,000,000					750,000,000
Notes payable																																																																88,917		88,917	117,572
Proceeds from debt																																																																		132,000	20,199	$ 372,374
Debt fair value																			$ 2,344,399													$ 425,000					$ 275,000																									2,344,399		355,668		355,668	282,173
Repayments of debt																																																																		40,480
Debt conversion price																																						$ 0.0005
Stock issued																			120,175													$ 175,000
Derivative loss																																																																		2,042,612	31,205
Extinguishment of Debt, Amount																																																																		27,000
Convertible Loans Eight [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Notes payable																																																																								$ 88,917
Convertible Loans Nine [Member]
Short-term Debt [Line Items]
Principal balance																																					$ 240,000
Shares issued, shares																																					16,000,000
Notes payable																																																																240,000		240,000	240,000
Debt discount																																					$ 40,000
Debt fair value																																																																960,000		960,000	576,000
Shares issued, amount																																					$ 4,688
Amortization of debt																													$ 22,344
Debt conversion price																																					$ 0.0005
Derivative loss																																					$ 240,000
Paycheck Protection Program Loan [Member]
Short-term Debt [Line Items]
Debt instrument, term																														24 months
Debt instrument, interest rate																														1.00%
Proceeds from debt																														$ 64,895
Economic Injury Disaster Loan [Member]
Short-term Debt [Line Items]
Debt instrument, term																													24 months
Debt instrument, interest rate																													3.75%
Accrued interest																																																																8,906		8,906	3,660
Proceeds from debt																													$ 150,000
Debt fair value																													731
Proceeds from related party																													$ 5,000
Loan Agreement [Member] | Note Payable One [Member]
Short-term Debt [Line Items]
Debt instrument, term																																																																							9 months
Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member]
Short-term Debt [Line Items]
Notes payable																																																																													$ 281,772	$ 175,000
Repayments of debt																$ 350,000																																													$ 25,000
Debt instrument, periodic payment																$ 50,000
Penalty for non-payment																																																																														$ 25,000
Sale of stock, shares																142,858
Stock issued, reverse stock splits																5,714,326
Proceeds from settlement																$ 450,000
Proceeds from initial legal settlement																350,000
Penalties on legal settlement																$ 100,000
Settlement Agreement [Member] | Southridge Partners LLP [Member]
Short-term Debt [Line Items]
Business combination, consideration transferred																																																									$ 281,772
Director [Member] | Loan Agreement [Member]
Short-term Debt [Line Items]
Principal balance																																																																							$ 200,000
Debt instrument, interest rate terms																																																																							interest calculated at 10% for the first month plus 12% after 30 days from funding
Debt instrument, interest rate																																																																							12.00%
Debt instrument, maturity date																																																																							Dec. 31, 2016
Accrued interest																			$ 40,000		$ 40,000																																					$ 40,000				$ 40,000		147,768		147,768	179,522
Interest expense																																																																		18,246	19,967
Director [Member] | Loan Agreement [Member] | Common Stock [Member]
Short-term Debt [Line Items]
Accrued interest																	$ 10,000
Shares issued, shares																	12,500,000
Former Director [Member] | Two Promissory Notes [Member]
Short-term Debt [Line Items]
Principal balance													$ 101,818
Debt instrument, interest rate																																																				12.00%
Accrued interest													21,023																																																			51,856		51,856	40,917
Notes payable																																																																$ 91,156		$ 91,156	$ 91,156
Proceeds from debt																																																				$ 200,000
Debt fair value																																																				$ 100,000
Debt settlement amount													$ 104,000																																														$ 88,500
Gain on settlement of debt																																																											$ 15,500
Repayment of debt settlement amount																							$ 88,500
Debt settlement, description																																																																		The remaining principal balance of $91,156 and accrued interest of $51,856 is being disputed in court and negotiation for settlement

SCHEDULE OF COMMON STOCK ISSUED

SCHEDULE OF COMMON STOCK ISSUED FOR CONVERSION OF DEBT (Details) - USD ($)	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020
Equity [Abstract]
Number of shares converted	2,500,000	5,700,000	27,070,000	67,380,000	137,700,000	107,817,770	107,133,333	250,000,000	250,000,000
Fair Value of Debt Converted	$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930	$ 64,691	$ 171,413	$ 275,000	$ 150,000

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($)	Nov. 15, 2021	Jun. 24, 2021	Jun. 02, 2021	Apr. 26, 2021	Mar. 03, 2021	Feb. 25, 2021	Oct. 05, 2020	Sep. 21, 2020	Feb. 18, 2020	Jan. 21, 2020	Oct. 30, 2017	Oct. 31, 2021	Aug. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Apr. 30, 2021	Mar. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Nov. 30, 2020	Oct. 31, 2020	Sep. 30, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jan. 31, 2020	Jun. 30, 2019	Apr. 30, 2019	Feb. 29, 2020	Jun. 30, 2021	Dec. 31, 2021	Aug. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2021	Nov. 18, 2021	Dec. 31, 2018	Oct. 31, 2017
Class of Stock [Line Items]
Common stock, shares authorized																															12,000,000,000		12,000,000,000	8,000,000,000		8,000,000,000
Available for distribution, cash per share											$ 0.133
Shares, Issued												12,500,000
Interest Payable, Current												$ 10,000																			$ 147,768		$ 147,768	$ 179,522
Fair value of issued shares												$ 200,000
Conversion of shares, shares		2,500,000	5,700,000	27,070,000	67,380,000	137,700,000	107,817,770	107,133,333	250,000,000	250,000,000
Conversion of shares, amount		$ 16,250	$ 35,340	$ 192,197	$ 599,682	$ 1,500,930	$ 64,691	$ 171,413	$ 275,000	$ 150,000
Debt instrument accrued interest																																		30,850
Debt instrument, face amount																																					$ 101,818
Notes payable																															1,135,257		1,135,257	1,346,057
Repayment of related party																																	182,741	22,150
Accrued interest																																					$ 21,023
Value of shares issued for services																																	174,000
Equity Compensation charge																															20,500		20,500
Note Payable [Member]
Class of Stock [Line Items]
Notes payable																									$ 50,000
Debt instrument, unamortized discount net issuance costs																									120,000
Original issue discount																									$ 20,000
Number of shares issued for settlement of debt																									125,000,000
Related Party Note [Member]
Class of Stock [Line Items]
Number of shares issued																								5,000,000
Fair value of issued shares																								$ 3,000
Repayment of related party																								$ 14,400
Seven Convertible Promissory Notes [Member]
Class of Stock [Line Items]
Conversion of shares, amount																																$ 511,319
Note Holder [Member]
Class of Stock [Line Items]
Number of shares issued																										75,000,000
Fair value of issued shares																										$ 45,000
Settlement and Restatement of Promissory Notes[Member]
Class of Stock [Line Items]
Number of shares issued																									36,000,000
Settlement and Restatement of Promissory Notes[Member] | Revision of Prior Period, Adjustment [Member]
Class of Stock [Line Items]
Number of shares issued																									10,000,000
Fair value of issued shares																									$ 119,700
Promissory Note [Member]
Class of Stock [Line Items]
Number of shares issued													20,866,250			2,000,000	11,000,000	29,072,500
Fair value of issued shares													$ 73,032			$ 15,200	$ 104,500	$ 343,056
Notes payable													183,619			4,000	6,000	166,926													$ 60,000		60,000	60,000
Original issue discount													16,693			12,000	11,000																					$ 10,000
Repayment of related party																	5,000
Accrued interest																		23,258
Loss on settlement of debt													$ 56,339			11,200	$ 98,500	$ 319,798
Settlement of debt																$ 8,500
Restricted Stock [Member] | Note Holder [Member]
Class of Stock [Line Items]
Number of shares issued for restricted stock																			25,000,000		1,500,000	10,000,000	1,000,000
Repayments of the promissory note																			$ 166,926		$ 84,000	$ 333,543	$ 22,000
Fair value of restricted shares																			$ 107,500		$ 900	$ 6,000	$ 700
Note Holder [Member]
Class of Stock [Line Items]
Conversion of shares, amount																														$ 2,344,399
Note Holder [Member] | Third Party [Member]
Class of Stock [Line Items]
Debt instrument accrued interest																				$ 140,000
Debt instrument, face amount																				20,000
Convertible note payable																				$ 75,900
Note Holder [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Conversion of shares, shares																					107,817,770	107,133,333							500,000,000	240,350,000
Conversion of shares, amount																					$ 22,000	$ 22,000							$ 175,000	$ 120,175
Debt instrument accrued interest																					$ 10,345	$ 10,140
Note Holder [Member] | Restricted Stock [Member] | Third Party [Member]
Class of Stock [Line Items]
Conversion of shares, shares																				100,000,000
Conversion of shares, amount																				$ 20,000
Consultant [Member]
Class of Stock [Line Items]
Number of shares issued for restricted stock															30,000,000												15,000,000	120,000,000
Fair value of restricted shares																											$ 6,000	$ 24,000
Number of shares issued for services														5,000,000																	25,000,000
Value of shares issued for services														$ 41,000																	$ 100,000
Equity compensation expense															$ 133,000																			$ 8,500
Equity Compensation charge																															20,500		20,500
Unrecognized compensation cost																															$ 20,500		$ 20,500
Consultant [Member] | 30 days Through November 2021 [Member]
Class of Stock [Line Items]
Number of shares issued for services															25,000,000
Consultant [Member] | Execution of Agreement [Member]
Class of Stock [Line Items]
Number of shares issued for services															5,000,000
Value of shares issued for services															$ 33,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized											20,000,000																				0		0	20,000,000
Number of shares issued											3,000,000
Preferred Stock, Par or Stated Value Per Share																															$ 0.001		$ 0.001	$ 0.001
Series A Preferred Stock Convertible Series B Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	3,000,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized																															20,000,000		20,000,000	0
Number of shares issued																	12,000,000
Preferred Stock, Par or Stated Value Per Share																	$ 0.001														$ 0.001		$ 0.001	$ 0.001
Shares, Issued																																			9,000,000
Accrued Salaries																																			$ 540,000
Series B Preferred Stock [Member] | Board of Directors [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	3,000,000

SCHEDULE OF WARRANTS ISSUED (De

SCHEDULE OF WARRANTS ISSUED (Details) - USD ($)	1 Months Ended
	Oct. 31, 2020	Aug. 31, 2020
Share-based Payment Arrangement [Abstract]
Number of Warrants	36,300,000	92,100,000
Fair value of warrants	$ 16,500	$ 38,500
Month of Expiration	October, 2022	August, 2022

SUMMARY OF WARRANTS OUTSTANDING

SUMMARY OF WARRANTS OUTSTANDING (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0017
Weighted Average Exercise Price, Warrants, Ending	$ 0.0017	$ 0.0017
Warrant [Member]
Number of warrants outstanding, Beginning	202,775,000	52,500,000
Weighted Average Exercise Price, Warrants, Beginning	$ 0.0017	$ 0.0028
Number of warrants, Exercised
Weighted Average Exercise Price, Warrants, Exercised
Number of warrants, Issued	410,403,571	200,275,000
Weighted Average Exercise Price, Warrants, Issued	$ 0.0018	$ 0.0014
Number of warrants, Expired	(166,475,000)	(50,000,000)
Weighted Average Exercise Price, Warrants, Expired	$ 0.0019	$ 0.0015
Number of warrants outstanding, Ending	446,703,571	202,775,000
Weighted Average Exercise Price, Warrants, Ending	$ 0.0017	$ 0.0017

SUMMARY OF FIXED PRICE WARRANTS

SUMMARY OF FIXED PRICE WARRANTS OUTSTANDING (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Number Outstanding	446,703,571	202,775,000
Weighted Average Contractual Life	8 months 1 day	11 months 4 days
Weighted Average Exercise Price	$ 0.0017	$ 0.0017
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	0.001	0.001
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.002	$ 0.03

STOCK WARRANTS (Details Narrati

STOCK WARRANTS (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2022	Nov. 30, 2020	Feb. 28, 2019	Dec. 31, 2018	Mar. 31, 2017	Mar. 03, 2016
Short-term Debt [Line Items]
Notes Payable				$ 1,135,257	$ 1,346,057
Fair value of warrants	$ 16,500	$ 38,500
Debt instrument, face amount										$ 101,818
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt instrument, face amount									$ 1,000,000
Two Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Number of warrants to purchase common stock					71,875,000			71,875,000
Warrants price					$ 0.002			$ 0.002
Debt instrument, face amount					$ 57,500		$ 57,500	$ 57,500
Debt instrument, original discount					7,500			$ 7,500
Three Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Number of warrants to purchase common stock				246,428,571
Warrants price				$ 0.002
Fair value of warrants				$ 409,374
Debt instrument, face amount					172,500
Debt instrument, original discount					22,500
One Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Notes Payable			$ 22,000			$ 22,000
Number of warrants to purchase common stock			44,000,000			44,000,000
Warrants price			$ 0.001			$ 0.001
Fair value of warrants						$ 7,370
Two Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Fair value of warrants				106,032	65,634
Three-year Warrant [Member]
Short-term Debt [Line Items]
Notes Payable											$ 80,000
Warrants, term											3 years
Number of warrants to purchase common stock											6,000,000
Warrants price											$ 0.005
Warrants, expiration date											Mar. 30, 2020
Five Year Warrant [Member]
Short-term Debt [Line Items]
Warrants, term												5 years
Number of warrants to purchase common stock												2,500,000
Warrants price												$ 0.03
Warrants, expiration date												Mar. 3, 2021
Fair value of warrants				$ 0	9
Warrant [Member]
Short-term Debt [Line Items]
Warrants price				$ 0.002
Number of warrants				$ 128,400
Warrant [Member] | Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Number of warrants to purchase common stock	36,300,000	92,100,000	44,000,000			44,000,000
Warrants price	$ 0.001
Fair value of warrants	$ 16,500	$ 38,500	$ 7,370	$ 195,178	$ 123,900
Debt instrument, face amount	16,500	38,500
Debt instrument, original discount	$ 1,650	$ 7,550
Money Warrants [Member]
Short-term Debt [Line Items]
Number of warrants to purchase common stock				128,400,000

SCHEDULE OF INCOME TAX EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Computed “expected” tax expense (benefit) - Federal	$ (2,750,059)	$ (161,529)
Computed “expected” tax expense (benefit) - State	(569,000)	(33,421)
Permanent differences and other	2,783,369	(145,667)
Change in valuation allowance	535,690	340,617
Provision for income taxes

SCHEDULE OF DEFERRED INCOME TAX

SCHEDULE OF DEFERRED INCOME TAX ASSETS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Reserve for prepaid inventory	$ 12,166	$ 23,573
Accrued salary	267,058	362,356
Recovery for receivables from officer		(25,979)
Net operating loss carryforwards	10,345,757	9,729,342
Valuation allowance	(10,624,981)	(10,089,292)
Net deferred income tax asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
valuation allowances increased	$ 535,690	$ 340,617
Operating Loss Carryforwards	40,800,000
Expired Between 2023 and 2037 [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	34,800,000
Incurred After December 31, 2017 [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 6,000,000

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued consulting fees	$ 161,550	$ 166,900
Accrued settlement expenses		35,000
Accrued payroll taxes	215,543	215,581
Accrued interest	469,040	351,830
Accrued others	5,337	11,121
Total	$ 851,470	$ 780,432

SCHEDULE OF PREPAID EXPENSES (D

SCHEDULE OF PREPAID EXPENSES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses
Supplier advances for future purchases	$ 294,162	$ 246,162
Reserve for supplier advances	(294,162)	(246,162)
Net supplier advances
Prepaid professional fees	65,650	10,000
Deferred stock compensation	20,500
Total	$ 86,150	$ 10,000

PREPAID EXPENSES (Details Narra

PREPAID EXPENSES (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expenses
Future reserve for purchases	$ 48,000	$ 21,303
Total valuation allowance for prepaid	$ 294,162	$ 246,162

CONVERTIBLE NOTES RECEIVABLE (D

CONVERTIBLE NOTES RECEIVABLE (Details Narrative) - USD ($)	Mar. 10, 2022	Dec. 31, 2021	Nov. 30, 2021	Dec. 31, 2020	Dec. 31, 2018
Short-term Debt [Line Items]
Debt Instrument, Face Amount					$ 101,818
Other Income [Member]
Short-term Debt [Line Items]
[custom:AmortizationOfNotesReceivables]		$ 12,980
Other Income [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
[custom:AmortizationOfNotesReceivables]	$ 26,950
Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount		3,751,760
Original issue discount		283,429		$ 101,448
Convertible Notes Payable [Member] | Unrelated Third Party [Member]
Short-term Debt [Line Items]
Debt Instrument, Face Amount			$ 286,550
Original issue discount		$ 13,070	$ 26,050
Debt Instrument, Convertible, Conversion Price			$ 0.01

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY MATURITY TABLE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2021	Feb. 28, 2016
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 80,396	$ 89,021
Short-term lease cost		18,698
Total lease cost	80,396	107,719
Operating ROU Assets	93,811	144,010
Operating lease obligations, current portion	77,673	82,873
Operating lease obligations, non-current portion		60,447
Total	$ 77,673	$ 143,320
Weighted average remaining lease term (in years) - operating leases	1 year	1 year 8 months 1 day
Weighted average discount rate-operating leases	8.00%	8.00%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 95,846	$ 98,780
2022	81,080
Total future lease payments	81,080		$ 6,500	$ 3,200
Less imputed interest	$ 3,407

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

Feb. 15, 2019

Oct. 12, 2018

Aug. 01, 2017

Apr. 12, 2017

Aug. 26, 2016

Feb. 28, 2016

Jul. 31, 2015

Feb. 28, 2021

Oct. 31, 2015

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2018

Dec. 31, 2016

Defined Benefit Plan Disclosure [Line Items]

Operating lease due

$ 3,200

$ 6,500

$ 81,080

Lease, description

the lease on a month-to-month basis until May 2020 when it was terminated

The lease calls for monthly payments of approximately $6,500 with a 4% increase each year

Common stock shares issued

7,330,985,964

6,955,197,214

1,000,000

Note issued

$ 535,787

$ 87,500

Shares issued, price per share

$ 0.18

Accrued liabilities for commissions, expense and taxes

$ 142,500

Equity compensation charges

$ 31,750

Accrued expenses

$ 19,150

$ 19,150

Share based compensation, shares not yet issued

1,500,000

1,500,000

Principal balance

$ 101,818

Accrued interest

$ 21,023

Loss contingency, allegations

The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief

Consulting Services Agreement [Member] | Restricted Stock [Member]

Defined Benefit Plan Disclosure [Line Items]

Consulting service term

5 years

Common stock shares issued

500,000

Debt instrument, interest rate

8.00%

Note issued

$ 50,000

Consultant Agreement [Member]

Defined Benefit Plan Disclosure [Line Items]

Share-based compensation arrangement by share-based payment

2,500,000

Consultant Agreement [Member] | Common Stock [Member]

Defined Benefit Plan Disclosure [Line Items]

Debt instrument periodic payment

$ 3,000

Recepto Pharm Leases [Member]

Defined Benefit Plan Disclosure [Line Items]

Operating lease due

$ 6,900

Lease, description

ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year

Paul Reid et Al [Member]

Defined Benefit Plan Disclosure [Line Items]

Loss contingency, damages sought, value

$ 315,000

Get Credit Healthy, Inc. and Rik Deitsch [Member]

Defined Benefit Plan Disclosure [Line Items]

Loss contingency, damages sought, value

$ 100,000

Payments for legal settlements

$ 104,000

CSA 8411, LLC [Member]

Defined Benefit Plan Disclosure [Line Items]

Loss contingency, damages sought, value

$ 100,000

Accrued interest

$ 51,856

Long-term debt

$ 91,156

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Feb. 28, 2022

Jan. 31, 2022

Oct. 31, 2021

Aug. 31, 2021

Apr. 30, 2021

Mar. 31, 2021

Feb. 28, 2021

Dec. 31, 2021

Dec. 31, 2020

Sep. 30, 2023

Aug. 31, 2022

Mar. 31, 2022

Feb. 28, 2019

Dec. 31, 2018

Oct. 31, 2017

Subsequent Event [Line Items]

Principal balance

$ 101,818

Debt instrument increase accrued interest

$ 30,850

Number of shares issued, value

$ 200,000

Promissory Note [Member]

Subsequent Event [Line Items]

Original issue discount

$ 16,693

$ 12,000

$ 11,000

$ 10,000

Number of shares issued

20,866,250

2,000,000

11,000,000

29,072,500

Number of shares issued, value

$ 73,032

$ 15,200

$ 104,500

$ 343,056

Subsequent Event [Member] | Restatement of Promissory Note [Member]

Subsequent Event [Line Items]

Principal balance

$ 183,619

Original issue discount

$ 16,693

Debt instrument increase accrued interest

$ 16,693

Number of shares issued

20,866,250

Number of shares issued, value

$ 54,252

Other income

37,559

Restated debt balance

183,619

Subsequent Event [Member] | Non-related Party [Member] | Promissory Note [Member]

Subsequent Event [Line Items]

Due from related party

$ 199,000

Debt instrument interest rate stated percentage

63.76%

Origination fees

$ 4,975

Convertible Notes Payable [Member]

Subsequent Event [Line Items]

Principal balance

$ 1,000,000

Convertible Notes Payable [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt conversion price

$ 0.00050

$ 0.00050

Convertible Notes Payable [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt conversion price

$ 0.00097

$ 0.00064

Convertible Notes Payable [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Principal balance

$ 6,000

Conversion of Stock, Shares Issued

12,000,000

Conversion of Stock, Amount Issued

$ 36,000

Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member]

Subsequent Event [Line Items]

Principal balance

$ 225,000

Original issue discount

$ 75,000

Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt conversion price

$ 0.0005

Convertible Notes Payable [Member] | Subsequent Event [Member] | Unrelated Third Parties [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt conversion price

$ 0.0008

Convertible Notes Payable [Member] | Forecast [Member]

Subsequent Event [Line Items]

Principal balance

$ 88,917